相关实验视频

Updated: Jul 25, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

估计患有三阴性乳腺癌的妇女的死亡率:"估计三阴性"工具

José P Leone¹, Noah Graham², Julieta Leone³

¹Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.

European journal of cancer (Oxford, England : 1990)

|June 25, 2023

概括

一种名为ESTIMATE-TN的新工具有助于预测三阴性乳腺癌 (TNBC) 患者乳腺癌死亡风险. 它估计了乳腺癌特异性死亡率 (BCSM) 和非BCSM的风险,帮助临床决策.

科学领域:

在瘤学瘤学.
生物统计学生物统计学
公共卫生公共卫生

背景情况:

由于其高死亡率,三阴性乳腺癌 (TNBC) 构成了重大挑战.
对乳腺癌特异性死亡率 (BCSM) 和非BCSM的准确风险分层对于TNBC的有效临床管理至关重要.
现有的工具可能无法充分解决TNBC患者死亡的竞争风险.

研究的目的:

开发和验证一个互动工具,ESTIMATE-TN,用于估计非转移性TNBC中BCSM和非BCSM的累积风险.
为临床医生提供数据驱动的资源,以帮助TNBC患者的个性化治疗决策.
根据患者和瘤特征量化TNBC死亡的竞争风险.

主要方法:

利用了监测,流行病学和最终结果 (SEER) 数据库,包括在2010-2017年期间诊断出TNBC的37,293名妇女.
开发了一种互动工具,ESTIMATE-TN,使用格雷的分发方法进行累积风险的非参数估计.
考虑了基线临床和病理变量,以预测7年期间BCSM和非BCSM的风险.

主要成果:

这项研究分析了37293名TNBC妇女的数据,主要是白人 (71.9%) 和50-69岁 (51.3%) 的女性.
估计TN显示了预测7年BCSM风险的能力 (例如,T2,N1,高等级TNBC的30.8%) 和非BCSM风险 (例如,2.8%).
3年后计算的残留风险显示,在随后的4年中,BCSM (17.4%) 和非BCSM (1.1%) 的可能性显著.

结论:

估计TN是一个有价值的交互工具,用于评估在TNBC中基于人群的BCSM和非BCSM风险.
该工具整合了患者和瘤的特征,以提供对竞争死亡风险的细微了解.
通过提供非转移性TNBC的个性化风险预测,ESTIMATE-TN可以显著帮助临床决策.

关键词:

计算器计算器计算器竞争的风险竞争的风险死亡死亡死亡死亡死亡死亡死亡死亡负面的ER负面的ER.幸存的生存方式

更多相关视频

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Kaplan-Meier Approach

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...